The protective effect of aminoguanidine on erectile function in diabetic rats is not related to the timing of treatment

BJU International

Volumn 94, Issue 3, 2004, Pages 429-432

  Usta, Mustafa F ^b   Bivalacqua, Trinity J ^a   Koksal, I Turker ^a   Toptas, Behiye ^a   Surmen, Sibel ^b   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Advanced glycation end products; Aminoguanidine; Diabetes mellitus; Erectile dysfunction

Indexed keywords

5 HYDROXYMETHYLFURFURAL; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; DRINKING WATER; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; CORPUS CAVERNOSUM NERVE; DIABETES MELLITUS; ERECTILE DYSFUNCTION; LONG TERM CARE; MALE; NERVE STIMULATION; NONHUMAN; PATHOGENESIS; PENIS ERECTION; PERIPHERAL NERVE; PRESSURE; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TISSUE LEVEL;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; IMPOTENCE; MALE; PENIS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 4344619156     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04937.x     Document Type: Article

References (24)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
2. Seftel AD, Vaziri ND, Ni Z et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997; 50: 1016-26
3. Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am 2001; 28: 209-16
4. Hakim LS, Goldstein I. Diabetic sexual dysfunction. Endocrinol Metab Clin North Am 1996; 25: 379-400
5. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Eng J Med 1989; 320: 1025-30
6. Cartledge JJ, Eardley I, Morrison JFB. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001; 87: 402-7
7. Usta MF, Tuncer M, Baykal A et al. Impact of chronic renal failure and peritoneal dialysis fluids on advanced glycation end product and iNOS levels in penile tissue: an experimental study. Urology 2002; 59: 953-7
8. Singh R, Barden A, Mori T, Beilin L Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-46
9. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-43
10. Usta MF, Bivalacqua TJ, Yang DY et al. The protective effect of aminoguanidine on erectile function in streptozotocin-diabetic rats. J Urol 2003; 170: 1437-42
11. Sell DR, Nelson JF, Monnier VM. Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat. J Gerontol a Biol Sci Med Sci 2001; 56: B405-11
12. Baykal-Erkiliç A, Erkiliç M, Ozben T. The effects of streptozocin-induced diabetes on renal plasma flow. Exp Clin Endocrinol 1995; 103: 367-72
13. Bivalacqua TJ, Usta MF, Champion HC et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 2003; 169: 1911-7
14. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 2353-62
15. Abdel-Rahman E, Bolton WK. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Invest Drugs 2002; 11: 565-74
16. Bucala R, Tracey KJ, Cerami A. Advanced glycasylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991; 87: 432-8
17. Sell DR. Ageing promotes the increase of early glycation Amadori product as assessed by epsilon-N-(2-furoylmethyl)-L-lysine (furosine) levels in rodent skin collagen. The relationship to dietary restriction and glycoxidation. Mech Ageing Dev 1997; 95: 81-99
18. Ulrich P, Zhang X. Pharmacological reversal of advanced glycation end-product-mediated protein crosslinking. Diabetologia 1997; 40: 157-9
19. Vasan S, Zhang X, Zhang X et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382: 275-8
20. Podlasek CA, Zelner DJ, Bervig TR, Gonzales CM, McKenna KE, McVary KT. Characterization and localization of nitric oxide synthase isoforms in the BB/WOR diabetic rat. J Urol 2001; 166: 746-55
21. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108: 1341-8
22. Cartledge JJ, Eardley I, Morrison JFB. Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int 2001; 87: 394-402
23. Degenhardt TP, Fu MX, Voss E et al. Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end- products in skin collagen of diabetic rats. Diabetes Res Clin Pract 1999; 43: 81-9
24. DeGroot J, Verzijl N, Budde M et al. Acummulation of advanced glycation end products decreases collagen turnover by bovine chondrocytes. Exp Cell Res 2001; 266: 303-10